Collectively, BSS/Lut stabilize tumor protein p53 inducible TP53INP2 expression by inhibiting ERK5 activity, upregulate activating receptors (NKG2D/NKp46) and effector molecules (TRAIL/GZMB), enhancing NK cell tumor recognition and cytotoxicity. The gene discussed is NCR1; the disease is neoplasm.